Health
Designer DNA therapies shown to effectively target cancer stem cells – The Science Board
Using an engineered DNA therapeutic agent to silence transcription factor genes reduced myeloma stem cell abundance and increased the survival of mice bearing human…
Multiple myeloma is the second most common blood cancer in the U.S. It generally recurs and is refractory (reoccurs and is unresponsive to treatments). Despite novel therapies, treatment toxicities continue to be a challenge for patients and clinicians.
In multiple myeloma, proinflammatory cytokines and antiviral interferons derived from bone marrow play a key role in disease progression, including activation of interleukin 6 (IL-6) with downstream interferon-response factor (IRF) signaling.
IRF4…
-
Noosa News22 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News20 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News20 hours agoDefence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash
-
General18 hours agoDairy farmers devastated by floods across parts of New South Wales